LPCN Overview

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.

Wall Street analysts forecast LPCN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is6.88 USD with a low forecast of 6.75 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lipocine Inc revenue for the last quarter amounts to 114.57K USD, decreased

Lipocine Inc. EPS for the last quarter amounts to -0.59 USD, increased 43.90

Lipocine Inc (LPCN) has 16 emplpoyees as of March 10 2026.

Today LPCN has the market capitalization of 43.75M USD.